Overview
Improving the Prognosis for Patients with BRAF-mutant and/or MSI-H mCRC
Interactive case-based CME activity
Click the"View Activity" button to view this activity.
View ActivityCME/CE is no longer available for this activity
Are you current with the latest updates with MSI-H/dMMR and/or BRAF-mutant metastatic colorectal cancer? In this case-based activity, leading expert and researcher, Dr. Dung Le discusses the latest approvals and recommendations for patients with MSI-H/dMMR and/or BRAF-mutant mCRC. This activity also features interactive case presentations which involve biomarker testing, treatment selection, and mitigating potential adverse events.
This activity is intended for oncologists, gastroenterologists, APPs, oncology nurses managing patients with metastatic colorectal cancer.
With the overwhelming pace of practice change in oncology, quality continuing education programs are an effective way to keep physicians up-to-date and enhance their confidence in incorporating new information and treatments into clinical practice. This education will help learners better understand appropriate biomarker testing in mCRC as well as the latest evidence and current treatment strategies for BRAF-mutant and/or MSI-H CRC.
Upon completion of this activity, participants will be able to:
• Describe appropriate biomarker testing recommended for mCRC and explain the importance of biomarker testing for therapy selection
• Interpret the latest clinical trial evidence for BRAF-mutant, MSI-H CRC
• Introduce recommended treatment approaches for BRAF-mutant, MSI-H CRC
• Describe appropriate biomarker testing recommended for mCRC and explain the importance of biomarker testing for therapy selection
• Interpret the latest clinical trial evidence for BRAF-mutant, MSI-H CRC
• Introduce recommended treatment approaches for BRAF-mutant, MSI-H CRC
This activity is supported through an Independent Medical Education grant from Merck & Co., Inc..
Dung Le, MD
Associate Professor of Oncology
Sidney Kimmel Cancer Center
Johns Hopkins University School of Medicine
Baltimore, MD
Associate Professor of Oncology
Sidney Kimmel Cancer Center
Johns Hopkins University School of Medicine
Baltimore, MD
The Academy for Continued Healthcare Learning (ACHL) requires that the faculty participating in an accredited continuing education activity disclose all affiliations or other financial relationships (1) with the manufacturers of any commercial product(s) and/or provider(s) of commercial services discussed in an educational presentation and (2) with any commercial supporters of the activity. All conflicts of interest have been mitigated prior to this activity.
The following financial relationships have been provided:
Dung Le, MD
Advisory Board/Panel Member: Bristol Myers Squibb
Discussion of Off-Label, Investigational, or Experimental Drug/Device Use: Infliximab for colitis secondary to immune checkpoint inhibitor therapy; mycophenolate for hepatitis secondary to immune checkpoint inhibitor therapy
ACHL staff members and others involved with the planning, development, and review of the content for this activity have no relevant affiliations or financial relationships to disclose.
The content for this activity was developed independently of the commercial supporter. All materials are included with permission. The opinions expressed are those of the faculty and are not to be construed as those of the publisher or grantor.
This educational activity was planned and produced in accordance with the ACCME Standards for Integrity and Independence in Accredited Continuing Education. Recommendations involving clinical medicine in a continuing medical education (CME/CE) activity must be based on evidence that is accepted within the profession of medicine as adequate justification for their indications and contraindications in the care of patients. All scientific research referred to, reported, or used in CME/CE in support or justification of a patient care recommendation must conform to the generally accepted standards of experimental design, data collection, and analysis.
This CME/CE activity might describe the off-label, investigational, or experimental use of medications and/or devices that may exceed their FDA-approved labeling. Physicians should consult the current manufacturers’ prescribing information for these products. ACHL requires the speaker to disclose that a product is not labeled for the use under discussion.
This activity will take approximately 45 minutes to complete. To receive credit, participants are required to complete the pretest, view the online activity and complete the posttest and evaluation. To receive credit, 66% must be achieved on the posttest. A certificate will be immediately available. There is no fee to participate in the activity or for the generation of the certificate.
The Academy for Continued Healthcare Learning is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
The Academy for Continued Healthcare Learning designates this enduring material for a maximum of 0.75 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
